MétaCan
Menu
Back to cohort

Phase I study of the PI3K/mTOR inhibitor gedatolisib (PF-05212384) in combination with docetaxel, cisplatin, and dacomitinib.

2016· article· en· W2736524699 on OpenAlexaff
Zev A. Wainberg, Geoffrey I. Shapiro, Giuseppe Curigliano, Rebecca Kristeleit, Stephen Leong, María Alsina, Michèle Milella, Carolyn D. Britten, Karen A. Gelmon, Anthony J. Olszanski, Ulka N. Vaishampayan, José A. López-Martín, Kenneth A. Kern, Kristen J. Pierce, Rachelle Perea, Brett E. Houk, Albiruni R. Abdul Razak

Bibliographic record

VenueJournal of Clinical Oncology · 2016
Typearticle
Languageen
FieldMedicine
TopicLung Cancer Treatments and Mutations
Canadian institutionsPrincess Margaret Cancer CentreBC Cancer Agency
Fundersnot available
KeywordsMedicineMucositisDocetaxelInternal medicineLung cancerOncologyCancerNauseaNeutropeniaRashAdverse effectCisplatinChemotherapyPharmacology

Abstract

fetched live from OpenAlex

2566 Background: Inhibition of phosphatidylinositol-3-kinase (PI3K)-mediated signaling may overcome resistance to chemotherapy or human epidermal growth factor receptor (EGFR) inhibitors. Gedatolisib (G) is a dual inhibitor of PI3K/mammalian target of rapamycin (mTOR) in development for solid tumors. Methods: This is an ongoing study to determine the maximum tolerated dose (MTD) and safety of G in combination with: 1) docetaxel: Arm A, in castrate resistant prostate cancer, advanced breast cancer (BC), or non-small cell lung cancer (NSCLC) patients (pts); 2) cisplatin: Arm B, in urothelial transitional cell cancer (TCC), triple negative BC (TNBC), NSCLC or ovarian cancer pts; 3) the pan-EGFR TKI dacomitinib: Arm C, in refractory HER2+BC, HER2+esophagogastric cancer, head and neck cancer, or EGFR-mutated NSCLC pts. Pts received a G lead-in dose 7 days (A, B) or 14 days (C) prior to day 1, followed by weekly intravenous (IV) G plus: docetaxel or cisplatin (75 mg IV every 3 weeks); or oral dacomitinib (30–45 mg/d). Secondary objectives included pharmacokinetics (PK), clinical efficacy (partial or complete response [PR or CR]), and associated biomarkers. Results: 74 pts (median prior therapies: 2; range: 0–6) received 90–260 mg/week of G in: A, 21; B, 21; and C, 32. The top drug related adverse events: A: neutropenia, mucositis, alopecia; B: nausea, fatigue, vomiting; and C: mucositis, diarrhea, nausea, fatigue. Cycle 1 dose limiting toxicities (DLTs) were: A: grade 3 mucositis (n = 1); B: no DLT; C: grade 3 mucositis (n = 1), pneumonitis (n = 1), rash (n = 1), and grade 2 fatigue (n = 1). PK parameters for G were similar regardless of combination agent. Best overall response was A: 4/21 PRs; B: 8/21 PRs (5 TNBC, 2 NSCLC, 1 TCC), and C: 6/32, (1 CR, 5 PRs). In Arm B, 3 of the 8 PRs (2 NSCLC, 1 TCC) had prior platinum exposure. Next generation sequencing involving PI3K data from a subset of patients is under evaluation. Conclusions: G can be combined with docetaxel, cisplatin, or dacomitinib, with manageable toxicity profiles and preliminary antitumor activity, even when heavily pre-treated. Due to portfolio prioritization, dose escalation and expansion continues in Arm B, with closure of Arms A and C (MTD not reached). Clinical trial information: NCT01920061.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.006
Threshold uncertainty score0.019

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0020.001
Bibliometrics0.0010.001
Science and technology studies0.0010.001
Scholarly communication0.0010.001
Open science0.0020.000
Research integrity0.0020.004
Insufficient payload (model declined to judge)0.0060.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.071
GPT teacher head0.494
Teacher spread0.422 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations9
Published2016
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical OncologySame topicLung Cancer Treatments and MutationsFrench-language works237,207